Research.Patient.info

GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic exploratory (Phase II)
"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial
This study is testing a new drug, milademetan, alongside an existing treatment, fulvestrant, for a specific type of advanced breast cancer. Researchers want to see if this combination helps shrink tumours or stop their growth in patients with certain genetic markers.
France